Pull to refresh
Logo
New European guidelines urge every heart patient to be tested for kidney disease

New European guidelines urge every heart patient to be tested for kidney disease

Rule Changes

First joint ESC-ERA guidelines target the two-way cycle in which heart and kidney disease accelerate each other

Yesterday: Coverage frames the 'heart-kidney cycle' story for wide audiences

Overview

Updated 57 minutes ago

In European medicine, the heart and kidney have been treated as separate problems. The first-ever joint guidelines from the European Society of Cardiology and the European Renal Association now treat them as one system that damages itself in a two-way cycle: kidney disease accelerates heart disease, and heart disease accelerates kidney failure.

The guidelines recommend that every patient diagnosed with cardiovascular disease get two cheap, routine tests: a blood test for estimated glomerular filtration rate, and a urine test for albumin-to-creatinine ratio. The goal is earlier detection of chronic kidney disease, a condition affecting roughly 100 million Europeans, so proven treatments can slow both diseases.

The treatment core is early use of RAS inhibitors, SGLT2 inhibitors, and statin-based therapy, all validated in recent trials to slow kidney decline and cut cardiovascular events. Catching the kidney disease patients do not know they have is the first step to getting them those drugs.

Why it matters

100 million Europeans with chronic kidney disease could be diagnosed years earlier if routine heart care adds two simple tests.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

100 million
Europeans estimated to have chronic kidney disease
ESC estimates about 100 million people in Europe live with CKD.
2
Routine screening tests recommended for heart patients
Blood eGFR and urine albumin-to-creatinine ratio, both simple and inexpensive.
First-ever
Joint ESC-ERA cardiovascular-kidney guidelines
First dedicated ESC guidelines on CVD with CKD, published August 2026 in the European Heart Journal.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

August 2026 September 2026

4 events Latest: Yesterday
Tap a bar to jump to that date
  1. Coverage frames the 'heart-kidney cycle' story for wide audiences

    Latest Media

    News reports emphasize the two-way damage cycle and the simple blood and urine tests that could break it.

  2. ESC press alert circulates on screening advice

    Media

    ScienceDaily and other outlets pick up the recommendation that every heart patient be tested for kidney disease.

  3. Guidelines presented at ESC Congress 2026 in Munich

    Conference

    Task force chairs Damman and Herrington outline the two-test screening recommendation to attending cardiologists.

  4. ESC and ERA publish first joint CVD-CKD guidelines

    Publication

    European Heart Journal carries new guidelines built on the STAMP-on-CKD framework: screen, triage, address risk, modify treatment, plan services.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2004-2008

Cardiorenal syndrome consensus (2004-2008)

The Acute Dialysis Quality Initiative and later the consensus groups formally defined cardiorenal syndromes: the clinical conditions where acute or chronic dysfunction of one organ induces dysfunction of the other. The definitions gave doctors a shared diagnostic language for a link long observed in practice.

Then

Clinicians gained formal criteria for diagnosing heart-kidney interaction syndromes.

Now

The concept legitimized joint management of the two organs and laid groundwork for cross-specialty guidelines.

Why this matters now

The ESC-ERA guidelines operationalize what the cardiorenal syndrome consensus named two decades ago. The diagnostic link is now embedded in routine screening recommendations for every heart patient.

2019-2023

SGLT2 inhibitor trials (2019-2023)

Trials including DAPA-CKD, EMPA-KIDNEY, and heart failure studies found that SGLT2 inhibitors protected both the kidneys and the heart, cutting kidney decline and cardiovascular events in patients with and without diabetes. RAS inhibitors and statins had long shown similar dual benefits.

Then

A class of diabetes drugs became standard therapy for heart and kidney protection.

Now

The trials provided the evidence base that makes the new ESC-ERA combination-therapy recommendation possible.

Why this matters now

The ESC guidelines lean directly on these trials. The drugs existed before; what changed is the confidence to combine them early in all CVD patients with kidney disease, which is exactly what the new guidance prescribes.

2026

US CKM syndrome guideline (2026)

The American Heart Association, American College of Cardiology, American Diabetes Association, and American Society of Nephrology issued a joint guideline for cardiovascular-kidney-metabolic syndrome, retiring and replacing the 2013 obesity guideline. It framed obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease as one interconnected condition.

Then

US clinicians gained a unified framework for treating metabolic, kidney, and heart conditions together.

Now

The guideline established a multi-organ, multi-specialty standard that became the reference for integrated care.

Why this matters now

The same year, on the other side of the Atlantic, the ESC and ERA produced their own joint framework. Both efforts converge on the same conclusion: heart, kidney, and metabolic disease belong to one care pathway, not separate silos.

Sources

(6)